Yonsei University Holding Company succeeded in transferring technology related to potential substances for a new medicine for anti-obesity. It is the first of such a case for a university technology index company in Korea. On March 29th, Yonsei signed a contract with Hyundai Pharm to hand over its technology related to “Composites Including Natural Extracts for Treatment or Prevention of Obesity or Fatty Liver,” and also agreed on how to conduct joint research in the future. Yonsei University Holding Company is expected to receive some KRW300 million in pre-payment as well as engineering fees. Hyundai Pharm will proceed with the development of a new anti-obesity medicine on the basis of this newly-gained technology. Park Tae-son, Professor of Foods & Nutrition at Yonsei, conducted the research for this technology and found that its effects far exceed those of the popular anorexigenic agent “sibutramine” through animal testing. Professor Park, also CEO of the Yonsei University Holding Company, said, “I am glad that the university’s successful research results are transferred to the relevant industry and applied to daily life. With obesity and metabolic diseases being considered as serious social problems, development of prevention and treatment medications using natural extracts is important.” Hyundai Pharm CEO Yoon Chang-hyun said, “Along with the increase in the number of obese people, anti-obesity medicine market will continue to grow. Through the technology we acquired, we aim to advance into the USD2 billion world anti-obesity medicine market after examination of potential substances, non-clinical and clinical testing, and more research on its commercialization.”